General MedicationsORALStandard

DESVENLAFAXINE SUCCINATE

Standard Dose

EQ 25MG BASE

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Prescription

Summary

Approval overview DESVENLAFAXINE SUCCINATE is listed in Drugs@FDA under application 210014 (ANDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient DESVENLAFAXINE SUCCINATE Form and strength TABLET, EXTENDED RELEASE;ORAL - EQ 25MG BASE Sponsor YICHANG HUMANWELL Submission history Latest submission status date: 2023-11-01 00:00:00.

Structured Monograph

Clinical summary

Approval overview DESVENLAFAXINE SUCCINATE is listed in Drugs@FDA under application 210014 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient DESVENLAFAXINE SUCCINATE Form and strength TABLET, EXTENDED RELEASE;ORAL - EQ 25MG BASE Sponsor YICHANG HUMANWELL Submission history Latest submission status date: 2023-11-01 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Prescription
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.